Literature DB >> 7733848

Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications.

K Zerres1, S Rudnik-Schöneborn.   

Abstract

OBJECTIVES: To describe the natural history in all types of proximal spinal muscular atrophy (SMA) and to propose a modified classification scheme that takes the long-term course of SMA into account.
DESIGN: Patients with proximal SMA were studied prospectively and retrospectively in a genetic study that was based on clinical and family data. PATIENTS: Four hundred forty-five patients with SMA were ascertained since 1985 through various departments of neurology and neuropediatrics, institutes of human genetics, and the German muscular dystrophy association (Deutsche Gesellschaft für Muskelkranke, Freiburg, Germany).
RESULTS: The study group was subdivided into patients with four types of SMA (ie, SMA types I, II, III, and IV) on the basis of achieved motor development and age at onset. Survival probabilities at 2, 4, 10, and 20 years of age were 32%, 18%, 8%, and 0%, respectively, in patients with SMA type I (those who were never able to sit) and 100%, 100%, 98%, and 77%, respectively, in patients with SMA type II (those who were able to sit but were unable to walk). Nineteen of 104 patients with SMA type II lost the ability to sit; this inability to sit was not of prognostic relevance. Patients with SMA type III (those who were able to walk [age at onset, younger than 30 years]) were subdivided into those with an age at onset before (SMA type IIIa) and after (SMA type IIIb) 3 years. The probabilities of being ambulatory at 10, 20, and 40 years after onset were 73%, 44%, and 34%, respectively, in patients with SMA type IIIa, and they were 97%, 89%, and 67%, respectively, in patients with SMA type IIIb.
CONCLUSIONS: The definition of long-term characteristics of SMA is helpful in providing medical care to families with members who have SMA and also in providing important information for future genotype-phenotype studies and therapeutic trials of patients with SMA. Our data indicate that the widely used classification schemes did not consider the broad spectrum of SMA so a practical modification was suggested.

Entities:  

Mesh:

Year:  1995        PMID: 7733848     DOI: 10.1001/archneur.1995.00540290108025

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  135 in total

1.  SMN dosage analysis and risk assessment for spinal muscular atrophy.

Authors:  Shuji Ogino; Robert B Wilson
Journal:  Am J Hum Genet       Date:  2002-06       Impact factor: 11.025

2.  Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos.

Authors:  B Schrank; R Götz; J M Gunnersen; J M Ure; K V Toyka; A G Smith; M Sendtner
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

3.  Spinal muscular atrophy--type I.

Authors:  M K M Hardart; R D Truog
Journal:  Arch Dis Child       Date:  2003-10       Impact factor: 3.791

4.  Carrier incidence for spinal muscular atrophy in southern Chinese.

Authors:  Vivian Chan; Ben Yip; Irene Yam; Patrick Au; Che-Kit Lin; Virginia Wong; Tai-Kwong Chan
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

5.  Low levels of Survival Motor Neuron protein are sufficient for normal muscle function in the SMNΔ7 mouse model of SMA.

Authors:  Chitra C Iyer; Vicki L McGovern; Jason D Murray; Sara E Gombash; Phillip G Zaworski; Kevin D Foust; Paul M L Janssen; Arthur H M Burghes
Journal:  Hum Mol Genet       Date:  2015-08-13       Impact factor: 6.150

6.  De novo rearrangements found in 2% of index patients with spinal muscular atrophy: mutational mechanisms, parental origin, mutation rate, and implications for genetic counseling.

Authors:  B Wirth; T Schmidt; E Hahnen; S Rudnik-Schöneborn; M Krawczak; B Müller-Myhsok; J Schönling; K Zerres
Journal:  Am J Hum Genet       Date:  1997-11       Impact factor: 11.025

7.  Rasch analysis of clinical outcome measures in spinal muscular atrophy.

Authors:  Stefan J Cano; Anna Mayhew; Allan M Glanzman; Kristin J Krosschell; Kathryn J Swoboda; Marion Main; Birgit F Steffensen; Carole Bérard; Françoise Girardot; Christine A M Payan; Eugenio Mercuri; Elena Mazzone; Bakri Elsheikh; Julaine Florence; Linda S Hynan; Susan T Iannaccone; Leslie L Nelson; Shree Pandya; Michael Rose; Charles Scott; Reza Sadjadi; Mackensie A Yore; Cynthia Joyce; John T Kissel
Journal:  Muscle Nerve       Date:  2013-07-26       Impact factor: 3.217

8.  c.835-5T>G Variant in SMN1 Gene Causes Transcript Exclusion of Exon 7 and Spinal Muscular Atrophy.

Authors:  Shuang Wu; Yun-Lu Li; Ning-Yi Cheng; Chong Wang; En-Lin Dong; Ying-Qian Lu; Jin-Jing Li; Xin-Xin Guo; Xiang Lin; Lu-Lu Lai; Zhi-Wei Liu; Ning Wang; Wan-Jin Chen
Journal:  J Mol Neurosci       Date:  2018-05-24       Impact factor: 3.444

9.  "I have SMA, SMA doesn't have me": a qualitative snapshot into the challenges, successes, and quality of life of adolescents and young adults with SMA.

Authors:  Allison Mazzella; Mary Curry; Lisa Belter; Rosángel Cruz; Jill Jarecki
Journal:  Orphanet J Rare Dis       Date:  2021-02-22       Impact factor: 4.123

10.  SMN-targeted therapeutics for spinal muscular atrophy: are we SMArt enough yet?

Authors:  Kathryn J Swoboda
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.